BLRX News and Press, BioLineRx Ltd. From 11/20/23

2023-11-20 13:54:04 ET BioLineRx Ltd. (BLRX) Q3 2023 Earnings Conference Call November 20, 2023 10:00 PM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO ...

2023-11-20 08:24:45 ET Losers: Syntec Optics Holdings ( OPTX ) -15% . Safe and Green Development Corp ( SGD ) -14% . Plus Therapeutics ( PSTV ) -14% reports new interim reSPECT-GBM phase 2 trial data at the society for NeuroOncology annual meeting. ...

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire - Received FDA Approval of APHEXDA® (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Auto...

AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...

BioLineRx Ltd. (BLRX) is expected to report $-0.18 for Q3 2023

2023-11-19 08:00:00 ET Even with the holiday-shortened Thanksgiving week, several prominent companies are set to unveil their quarterly results next week. The docket includes tech giant Nvidia ( NASDAQ: NVDA ), as well as Zoom Video ( NASDAQ: ZM ), HP Inc. ( NYSE: HPQ ...

2023-11-17 12:56:05 ET More on biolinerx Assessing BioLineRx As A Buy After Drug Approval BioLineRx Ltd. (BLRX) Q2 2023 Earnings Call Transcript BioLineRx announces closing of exclusive license agreement with GloriaBio BioLineRx gains after winning first FDA ...

2023-11-17 09:47:47 ET Major earnings expected before the bell on Monday include: BioLineRx ( BLRX ) Niu Technologies ( NIU ) VEON ( VEON ) Zepp Health ( ZEPP ) For Seeking Alpha's  earnings season calendar, click here . For further detai...

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023 PR Newswire - Management to Hold Conference Call at 10:00 a.m. EST - TEL AVIV, Israel , Nov. 13, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial sta...

2023-11-05 02:15:00 ET Summary Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for its next-gen PARP1 inhibitor to Germany’s Merck KGaA. BioLineRx, an Israeli biotech, out-licensed China rights to a stem cell mobilizer for multiple myeloma and stem cell disease...